{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T20:03:52Z","timestamp":1778011432099,"version":"3.51.4"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Interstitial Pneumonitis (IP) is one of the pulmonary complications associated with mammalian Target of Rapamycin-Inhibitors (mTOR-Is). Sirolimus and everolimus belong to mTOR-Is. According to studies, IP is caused by both.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>This is a case report in a kidney transplant recipient. We want to present a case of IP after 50 months of sirolimus consumption. Sirolimus was discontinued, and cyclosporine was started. Thirty-seven months later, everolimus was prescribed as an alternative to cyclosporine due to the recurrence of skin Squamous Cell Carcinoma (SCC). Fortunately, no respiratory manifestations were seen after more than 8 years of everolimus consumption.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In conclusion, in cases with sirolimus-induced IP, discontinuation of sirolimus and replacement with everolimus are recommended after resolving clinical symptoms and pulmonary lesions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-024-03661-4","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T06:32:34Z","timestamp":1731393154000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Sirolimus-induced pulmonary toxicity without recurrence more than 8 years after everolimus replacement in a renal transplant patient with recurrent skin SCC: a case report"],"prefix":"10.1186","volume":"25","author":[{"given":"Golsa","family":"Ghasemi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahrzad","family":"Shahidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,12]]},"reference":[{"issue":"6","key":"3661_CR1","first-page":"510","volume":"14","author":"G Ghasemi","year":"2020","unstructured":"Ghasemi G, Shahidi S, Farajzadegan Z, Shahidi S, Mohammadi M. Sirolimus dose requirement in kidney transplant recipients in Iran. Iran J Kidney Dis. 2020;14(6):510.","journal-title":"Iran J Kidney Dis"},{"issue":"2","key":"3661_CR2","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.canlet.2012.02.004","volume":"321","author":"A Basu","year":"2012","unstructured":"Basu A, Liu T, Banerjee P, Flynn E, Zurakowski D, Datta D, et al. Effectiveness of a combination therapy using calcineurin inhibitor and mTOR inhibitor in preventing allograft rejection and post-transplantation renal cancer progression. Cancer Lett. 2012;321(2):179\u201386.","journal-title":"Cancer Lett"},{"issue":"4","key":"3661_CR3","doi-asserted-by":"publisher","first-page":"e0194975","DOI":"10.1371\/journal.pone.0194975","volume":"13","author":"S Wolf","year":"2018","unstructured":"Wolf S, Hoffmann VS, Habicht A, Kauke T, Bucher J, Schoenberg M, et al. Effects of mTOR-Is on malignancy and survival following renal transplantation: a systematic review and meta-analysis of randomized trials with a minimum follow-up of 24 months. PLoS ONE. 2018;13(4):e0194975.","journal-title":"PLoS ONE"},{"key":"3661_CR4","doi-asserted-by":"crossref","unstructured":"Imamura R, Tanaka R, Taniguchi A, Nakazawa S, Kato T, Yamanaka K et al. Everolimus reduces Cancer incidence and improves patient and graft survival rates after kidney transplantation: a Multi-center Study. J Clin Med. 2022;11(1).","DOI":"10.3390\/jcm11010249"},{"issue":"7","key":"3661_CR5","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1681\/ASN.2018010009","volume":"29","author":"J Pascual","year":"2018","unstructured":"Pascual J, Berger SP, Witzke O, Tedesco H, Mulgaonkar S, Qazi Y, et al. Everolimus with reduced calcineurin inhibitor exposure in renal transplantation. J Am Soc Nephrol. 2018;29(7):1979\u201391.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"3661_CR6","first-page":"297","volume":"33","author":"G Molas Ferrer","year":"2013","unstructured":"Molas Ferrer G, Molas-Ferrer G, Soy Muner D, Soy-Muner D, Anglada Mart\u00ednez H, Anglada-Mart\u00ednez H, et al. Interstitial pneumonitis as an adverse reaction to mTOR inhibitors. Nefrolog\u00eda (English Edition). 2013;33(3):297\u2013300.","journal-title":"Nefrolog\u00eda (English Edition)"},{"issue":"3","key":"3661_CR7","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s11523-013-0289-2","volume":"9","author":"BA Gartrell","year":"2014","unstructured":"Gartrell BA, Ying J, Sivendran S, Boucher KM, Choueiri TK, Sonpavde G, et al. Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis. Target Oncol. 2014;9(3):195\u2013204.","journal-title":"Target Oncol"},{"issue":"3","key":"3661_CR8","doi-asserted-by":"publisher","first-page":"630A","DOI":"10.1378\/chest.1822854","volume":"145","author":"L Molinari","year":"2014","unstructured":"Molinari L, Rosenbaum T, Aruj P, Alvarez C, Aguirre C, Sobrino E. Sirolimus-Associated interstitial pneumonia in four renal transplant recipients. Chest. 2014;145(3):630A.","journal-title":"Chest"},{"issue":"1","key":"3661_CR9","first-page":"58","volume":"28","author":"S Shahidi","year":"2023","unstructured":"Shahidi S, Vahdat S, Atatpour A, Meshkinfar S. The side effect profile of sirolimus and its relationship with some variables: a retrospective study of Iranian renal transplant patients. J Res Med Sci. 2023;28(1):58.","journal-title":"J Res Med Sci"},{"key":"3661_CR10","doi-asserted-by":"crossref","unstructured":"Nishino M, Brais LK, Brooks NV, Hatabu H, Kulke MH, Ramaiya NH. Drug-related pneumonitis during mTOR inhibitor therapy in patients with neuroendocrine tumors: A radiographic pattern-based approach. European journal of cancer (Oxford, England: 1990). 2016; 53:163.","DOI":"10.1016\/j.ejca.2015.10.015"},{"key":"3661_CR11","first-page":"101109","volume":"30","author":"AM Alkhunaizi","year":"2020","unstructured":"Alkhunaizi AM, Al-Khouzaie TH, Alsagheir AI. Sirolimus-induced interstitial lung disease and resolution after conversion to everolimus. Respir Med Case Rep. 2020;30:101109.","journal-title":"Respir Med Case Rep"},{"issue":"1","key":"3661_CR12","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1046\/j.1600-6135.2003.00292.x","volume":"4","author":"AA Haydar","year":"2004","unstructured":"Haydar AA, Denton M, West A, Rees J, Goldsmith DJ. Sirolimus-induced pneumonitis: three cases and a review of the literature. Am J Transpl. 2004;4(1):137\u20139.","journal-title":"Am J Transpl"},{"issue":"10","key":"3661_CR13","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.jcma.2013.06.009","volume":"76","author":"LK Huang","year":"2013","unstructured":"Huang LK, Tsai MJ, Chang SC. Unusual radiological presentation of sirolimus-associated pneumonitis. J Chin Med Assoc. 2013;76(10):588\u201392.","journal-title":"J Chin Med Assoc"},{"issue":"5","key":"3661_CR14","doi-asserted-by":"publisher","first-page":"437","DOI":"10.5144\/0256-4947.2014.437","volume":"34","author":"L Nazer","year":"2014","unstructured":"Nazer L, Alnajjar T, Salah S, Khzouz J, Alfaqeer N, Qandeel M. Fatal case of cryptogenic organizing pneumonia associated with everolimus. Ann Saudi Med. 2014;34(5):437\u20139.","journal-title":"Ann Saudi Med"},{"issue":"5","key":"3661_CR15","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/tri.12275","volume":"27","author":"MC Baas","year":"2014","unstructured":"Baas MC, Struijk GH, Moes DJA, van den Berk IA, Jonkers RE, de Fijter JW, et al. Interstitial pneumonitis caused by everolimus: a case\u2013cohort study in renal transplant recipients. Transpl Int. 2014;27(5):428\u201336.","journal-title":"Transpl Int"},{"issue":"1","key":"3661_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1756-0500-6-471","volume":"6","author":"C Sibertin-Blanc","year":"2013","unstructured":"Sibertin-Blanc C, Norguet E, Duluc M, Louis G, Seitz J-F, Dahan L. Severe hypersensitivity pneumonitis associated with everolimus therapy for neuroendocrine tumour: a case report. BMC Res Notes. 2013;6(1):1\u20133.","journal-title":"BMC Res Notes"},{"key":"3661_CR17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2174\/1874306401206010063","volume":"6","author":"M Schwaiblmair","year":"2012","unstructured":"Schwaiblmair M, Behr W, Haeckel T, M\u00e4rkl B, Foerg W, Berghaus T. Drug induced interstitial lung disease. Open Respir Med J. 2012;6:63\u201374.","journal-title":"Open Respir Med J"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-024-03661-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-024-03661-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-024-03661-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T19:02:25Z","timestamp":1731438145000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-024-03661-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,12]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3661"],"URL":"https:\/\/doi.org\/10.1186\/s12882-024-03661-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3676282\/v1","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,12]]},"assertion":[{"value":"28 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"To use the patient\u2019s information, the study was explained to the patient before joining the study, and written informed consent was obtained. This study has been approved by Isfahan University of Medical Sciences, Research Ethics Committee (Address link:\n                      \n                      ).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the participant for the publication of the case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"406"}}